Collection of Circulating Biomarkers in Pancreatic Cancer

• Sponsor: Abramson Cancer Center of the University of Pennsylvania (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05743049
• Collaborator: (none)
• Enrollment: 30
• Location: 1
• Anticipated Duration (Months): 12
• Patients Per Site Per Month: 2.5

Study Details

Study Description

Brief Summary

This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.

Condition or Disease	Intervention/Treatment	Phase
Pancreas Cancer	Other: Obtaining blood for analysis of various circulating biomarkers

Study Design

• Study Type: Observational
• Anticipated Enrollment: 30 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Protocol to Permit Collection of Circulating Biomarkers in Pancreatic Cancer
• Anticipated Study Start Date: Feb 15, 2023
• Anticipated Primary Completion Date: Aug 12, 2023
• Anticipated Study Completion Date: Feb 15, 2024

Arms and Interventions

Arm	Intervention/Treatment
Blood specimens Collection of blood for analysis of various circulating biomarkers in patients with pancreatic adenocarcinoma.	Other: Obtaining blood for analysis of various circulating biomarkers; 4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period

Outcome Measures

Primary Outcome Measures

1. To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use. [The frequency of research blood collection will be up to 4 times in an 8 week period.]

Secondary Outcome Measures

1. To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response. [The frequency of research blood collection will be up to 4 times in an 8 week period.]

2. To integrate the data and specimens to permit the most informative clinical-biologic research platform. [The frequency of research blood collection will be up to 4 times in an 8 week period.]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma

• The subject must be a patient of the University of Pennsylvania

• The subject must be able to provide informed consent

• The subject must be 18 years of age or older

Exclusion Criteria:

. Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Abramson Cancer Center at University of Pennsylvania	Philadelphia	Pennsylvania	United States	19104

Sponsors and Collaborators

• Abramson Cancer Center of the University of Pennsylvania

Investigators

• Principal Investigator: Mark O'Hara, MD, Abramson Cancer Center, University of Pennsylvania

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Abramson Cancer Center of the University of Pennsylvania
• ClinicalTrials.gov Identifier: NCT05743049
• Other Study ID Numbers: UPCC 20222; 852628
• First Posted: Feb 24, 2023
• Last Update Posted: Feb 24, 2023
• Last Verified: Feb 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Pancreatic Neoplasms

Study Results

No Results Posted as of Feb 24, 2023